SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast ($MVST) is surging, with the community focused on its potential for a short squeeze and its progress in EU revenues. Many believe $MVST is undervalued compared to peers and anticipate a significant move upwards, fueled by positive technical indicators and upcoming earnings. The community is actively discussing its small float, low short interest, and potential for further growth.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as the community discusses a significant price swing and potential short squeeze, with some attributing the volatility to broader sector movements and others pointing to company-specific catalysts. Bullish sentiment revolves around the company's position as a domestic antimony producer amid increasing geopolitical tensions related to rare earth mineral supply. Many are speculating about potential government support and long-term growth prospects.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

OMER is trending amid renewed community excitement, with many expressing anticipation for a potential short squeeze and significant upward movement. Discussions are focused on a recent deal with Novo Nordisk, with some speculating about the potential for additional news and a potential impact on the company's market capitalization. The community seems bullish, viewing OMER as undervalued in the biotech sector.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation around potential cannabis rescheduling, with some community members pointing to a video from a senior advisor to President Trump as a catalyst. A trading halt and subsequent price movement in cannabis stocks have intensified the buzz, as investors discuss potential catalysts like Veterans Day. Community members are actively debating the timing and impact of any policy changes.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is trending amid discussions around a recent offering and its potential impact on the stock. While some community members express concern over dilution, others view it as a strategic move to fuel growth in the quantum computing sector, pointing to upcoming catalysts and strong backing from institutional investors. The stock's recent gains and high trading volume are also fueling the conversation.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending amid escalating U.S.-China trade tensions and China's export restrictions on rare earth materials, vital for tech and defense, which are driving interest in Western producers. Community members are actively discussing potential price targets, loading up on dips, and anticipating further upside due to the increasing strategic importance of rare earth elements. Some investors believe the stock is overvalued, while others suggest the company is still undervalued, anticipating government action.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as investors discuss potential catalysts, including partnerships and upcoming earnings, with a focus on PIF growth. Community members are debating the company's long-term potential against its current valuation, profitability, and the CEO's performance. Some traders are noting technical indicators and potential short squeezes, while others express concern over management and recent price action compared to peers.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as community members discuss its potential breakout and recent partnership with OpenAI, with many eyeing call options. Some traders express concerns about valuation and overbought conditions, while others point to strong international sales and AI integration as growth drivers. Overall sentiment appears mixed, with a focus on short-term trading opportunities.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is trending due to increased interest in rare earth minerals amid escalating trade tensions between the U.S. and China, with community members speculating on government investment and potential for significant growth. Discussions revolve around the company's strategic positioning in the rare earth supply chain and its potential to benefit from efforts to reduce reliance on Chinese resources. Some traders are wary of a potential pullback after a recent surge, while others remain bullish, anticipating further gains.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

SDOT is trending as community members discuss its potential due to a low float and news regarding possible trade measures impacting cooking oil. Some traders are pointing to the company's potential to move into crypto, while others highlight strong revenue despite past dilution concerns. Overall, the stock sees speculative interest driven by macro events and sector momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Xilio Therapeutics ended nearly 8% higher on Tuesday after the company reported positive early trial results for its cancer drug XTX301, began dosing patients in Phase 2, and secured a $17.5 million milestone payment from Gilead Sciences.Xilio said Phase 1 data for XTX301, a tumor-activated IL-12 therapy, showed anti-tumor activity in patients with advanced solid tumors, including two partial responses, while most side effects were mild or moderate.&nbsp;The treatment also sustained interferon gamma signaling across cycles, supporting the company’s approach of reprogramming “cold” tumors into inflamed “hot” ones.Based on the findings, Xilio selected a recommended Phase 2 dose and schedule and has begun treating patients in the Phase 2 portion of its ongoing Phase 1/2 trial in the U.S, which will enroll about 40 participants.&nbsp;Enrollment in Phase 1A has been completed, and Phase 1B expansion is still underway.The milestone payment from Gilead, tied to the start of Phase 2, extends Xilio’s cash runway into the first quarter of 2027. As of June 30, the company held $121.6 million in cash and equivalents and expects to receive the Gilead payment in the fourth quarter of 2025.Under their March 2024 global license agreement, Gilead may take over development and commercialization of XTX301 after reviewing clinical data, with an option fee of $75 million.&nbsp;Xilio could receive up to $500 million in additional development, regulatory and sales milestones, plus tiered royalties ranging from high single digits to mid-teens on global net sales.On Stocktwits, retail sentiment for Xilio was ‘bullish’ amid a 2,333% surge in 24-hour message volume.One user said that the stock had “solid news” but needed more trading volume to push through the $0.80 level.<stembedurl>https://stocktwits.com/MrTicker/message/627979369</stembedurl>Another user predicted the shares would climb quickly, noting it was “super hard to get shares.”&nbsp;They highlighted that Xilio held about $140 million in cash against a roughly $38 million market cap, arguing the market had assigned little to no value to its partnerships, assets, or even its cash balance, and suggesting a reprice was likely.<stembedurl>https://stocktwits.com/SteadyTrade55/message/627979366</stembedurl><a href="https://stocktwits.com/symbol/XLO">Xilio’s stock</a> has declined 21.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Xilio’s stock has declined 21.5% so far in 2025. (Photo credit: Getty Images)

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

The company has begun dosing patients in Phase 2 of its trial for XTX301, a tumor-activated IL-12 therapy that showed two partial responses in early testing and was generally well tolerated.

Equity

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of -100.00% and -10.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

TD Cowen Remains a Buy on Xilio Therapeutics (XLO)

TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO Research Report) yesterday. The company's shares closed yesterday...

Xilio Therapeutics reports Q4 results

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...

12 titoli sanitari in movimento, sessione regolare del 01/04/2024

Titoli in rialzo
Le azioni di Sunshine Biopharma (NASDAQ:SBFM) hanno fatto segnare +84,29% a 0,11 dollari durante la sessione regolare di luned .
Le azioni di Xilio Therapeutics (NASDAQ:XLO) sono...

12 acciones de salud en movimiento en la sesi n intrad a del 01/04/2024

Acciones al alza
Sunshine Biopharma (NASDAQ:SBFM) se anotaron un alza del 93,22% para establecerse en los 0,12 d lares durante la sesi n del regular del lunes.
Xilio Therapeutics (NASDAQ:XLO) ganaron...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 29/03/2024

Gagnants
Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market.
Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...

12 titoli sanitari in movimento, pre-market del 29/03/2024

Titoli in rialzo
Le azioni di Avalo Therapeutics (NASDAQ:AVTX) sono cresciute del 289,05% a 18,48 dollari durante la sessione pre-market di venerd .
Il titolo Xilio Therapeutics (NASDAQ:XLO) salito...

Xilio Therapeutics announces $11.3M private placement equity financing

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Xilio Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$0.761
Prev Close	$0.759
Open	$0.7671
Dividend Yield	0.00%
50-Day Moving Average	$0.7407
Beta	0.69
Avg. Volume	901,210.71
PE Ratio	-0.99

52-Week High	$1.70
52-Week Low	$0.615
Market Capitalization	$39.34M
EPS (Annual)	-$1.09
Price to Book	5.56
Revenue Per Employee	$99,125.00
Enterprise Value/EBITDA	N/A

XLO
Xilio Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest XLO News

XLOXilio Therapeutics Inc